On November 13, the U.S. Environmental Protection Agency (EPA) announced that it would take comments on 24 studies it had already considered in its draft risk evaluation for HHCB. The notice appeared in the Federal Register on November 16. Comments must be received by December 16, 2026. The 30-day window covers only these newly accessible materials and does not reopen the draft risk evaluation as a whole.

The 24 studies were submitted by industry and considered when the EPA prepared the draft. An administrative issue in the HERO research database kept the studies from public view during the original comment period. The EPA restored access on October 14. The November notice gives the public a chance to comment on those studies; it does not mean the EPA first received or considered them in November. The notice points to a list in the data availability memorandum in docket EPA-HQ-OPPT-2018-0430.

HHCB, also known as Galaxolide, is a synthetic musk used in fragrances. Its CAS number is 1222-05-5. The uses listed by the EPA include all-purpose and bathroom cleaners, liquid laundry detergents, fabric softeners and air-care products. These are uses considered in the evaluation, not a list of products. A product's scent alone does not show whether it contains HHCB.

The status of each document matters. In its April draft, the EPA provisionally found no unreasonable risk to health or the environment from HHCB under the conditions of use it evaluated. The Science Advisory Committee on Chemicals peer-reviewed the draft and other materials from June 8 to 12. The report forwarded on August 24 presents the committee's review, not the EPA's final risk evaluation. Section 6 of the U.S. Toxic Substances Control Act distinguishes risk evaluation from rules issued after a finding of unreasonable risk. The November notice requests comments: it neither restricts use nor makes a finding about a finished product's safety or market access.

Cleaning product makers that buy fragrances can check the trade name, the substance identifier and the grade actually purchased as separate details. Health Canada's ingredient database also lists Galaxolide as a common name for the substance and gives the same CAS number, 1222-05-5. That number helps identify the substance. The relevant supplier documents and formulation records are still needed to establish which grade was purchased and how the finished product is used.

To decide whether this evaluation relates to a particular formulation, product development and purchasing teams can first check the version of their supplier documents, then compare the finished product's intended use and how it is used. That helps distinguish what their records support from what still needs to be confirmed with the supplier. Public communications should likewise distinguish the release of research materials from a published final evaluation or rule. A comment deadline is not a date on which products must be reformulated or taken off sale.

Diagram of study documents and a public comment bubble
The comment period covers studies whose public access was restored. It is not a final risk evaluation or a decision to change formulations.